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Abstract
Background: Pregnancy-associated malaria (PAM) is a serious consequence of the adhesion to the placental receptor
chondroitin sulfate A (CSA) of Plasmodium falciparum-infected erythrocytes (PE) expressing the large cysteine-rich multi-
domain protein var2CSA. Women become resistant to PAM, and develop strain-transcending immunity against CSA-binding
parasites. The identification of var2CSA regions that could elicit broadly neutralizing and adhesion-blocking antibodies is a
key step for the design of prophylactic vaccine strategies.
Methodology: Escherichia coli expressed var2CSA DBL domains were refolded and purified prior to immunization of mice
and a goat. Protein-G-purified antibodies were tested for their ability to block FCR3
CSA-infected erythrocytes binding to
placental (BeWo) and monkey brain endothelial (ScC2) cell lines using a flow cytoadhesion inhibition assay mimicking
closely the physiological conditions present in the placenta at shear stress of 0.05 Pa. DBL5-e, DBL6-e and DBL5-6-e induced
cross-reactive antibodies using Alum and Freund as adjuvants, which blocked cytoadhesion at values ranging between 40
to 96% at 0.5 mg IgG per ml. Importantly, antibodies raised against recombinant DBL5-e from 3 distinct parasites genotypes
(HB3, Dd2 and 7G8) showed strain-transcending inhibition ranging from 38 to 64% for the heterologuous FCR3
CSA.
Conclusions: Using single and double DBL domains from var2CSA and Alum as adjuvant, we identified recombinant
subunits inducing an immune response in experimental animals which is able to block efficiently parasite adhesion in a flow
cytoadhesion assay that mimics closely the erythrocyte flow in the placenta. These subunits show promising features for
inclusion into a vaccine aiming to protect against PAM.
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Introduction
Plasmodium falciparum-infected erythrocytes (PE) sequester in the
placenta by adhering to chondroitin sulfate A (CSA) expressed on
the surface of human syncytiotrophoblasts [1]. The massive
sequestration of parasites is believed to cause pregnancy-associated
malaria (PAM) in primigravid women, since in multigravid women
improved health is linked to highly reduced parasite sequestration
[2]. Naturally acquired antibodies protect against PAM as a
function of parity through a mechanism that appears to be IgGs
blocking binding of PE to CSA [3–5]. The VAR2CSA gene
product is expressed on the surface of PE selected on CSA and on
parasite isolates from infected placentas [6–10]. Although several
DBL domains are linked to CSA binding [11], the expression of
full length recombinant var2CSA (exon 1) suggest that high affinity
binding to CSA requires the cooperation of several domains
[12,13]. Disruption of this gene leads to the irreversible loss of
binding to CSA, pointing to this molecule as the prime target for
intervention strategies for PAM [14]. Two major problems are
linked to var2CSA. First, it is a protein with a very large external
domain of approximately 300 kDa. Second, although the gene is
found in all P. falciparum isolates, some regions show considerable
genetic diversity [15]. A major ongoing effort in several
laboratories is the identification of semi-conserved subunit regions
that induce efficiently adhesion-blocking immune response in
animals. Several recent publications have reported some progress
into this direction [16–18]. In these studies, the evaluation of
cytoadhesion inhibition has been based on assays using purified
non-placental sources of CSA bound to plastic dishes (static
assays). This test is a very convenient assay suitable for high
throughput screening of sera. It does, however, neither mimic the
exact CSA-sulfation pattern and CSA density on placental cells
nor the shear stress due to placental blood flow.
In this study, four different DBL5-e, two different double DBL5-
6-e and one DBL6-e domains were produced in an E. coli
expression system. Immunization protocols using Freund’s and
Alum as adjuvants were used to raise antisera in mice and a goat.
We report significant levels of inhibition of parasite adhesion for
purified IgG obtained with both adjuvants, using an in vitro assay
that mimics very closely the physiological situation in the placenta
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12558during infection. Purified IgGs from animals immunized with
homologous and heterologous var2CSA DBL regions were
evaluated for their capacity to block FCR3
CSA PEs binding to a
placental cell line (BeWo) using a flow cytoadhesion chamber. We
report here that domains at the C-terminal region of var2CSA
external domain generated high levels of strain-transcending
cytoadhesion-blocking antibodies.
Methods
Ethics Statement
All animal experiments were approved and conducted in
accordance with the Institut Pasteur Biosafety Committee.
Animals were maintained in an animal facility which is licensed
by the French Ministry of Agriculture (agreement B 75 15-08
dated May 22, 2008). Facility has central air conditioning
equipment that maintains constant temperature of 2262uC. Air
is renewed at least 20 times per hour in animal rooms. Fluorescent
light is provided with a 12:12 h light:dark cycle.
In France, review of experimental protocols by an ethic
committee is not mandatory. All researchers performing animal
experiments in this study were directly responsible for the
experimental protocols and obtained individual licenses from the
French Ministry of Agriculture.
1. Prokaryotic expression, refolding and purification
1.1. Cloning. Genes encoding FCR3 var2CSA (accession
AY372123) DBL5-e (residues 2003–2281), DBL6-e (residues
2297–2590) and double DBL5-6-e (residues 2003–2590), 7G8
var2CSA (accession EF614233) DBL5-e (residues 2019–2311),
Dd2 var2CSA DBL5-e (residues 2009–2291), and HB3-1 DBL5-e
(residues 2026–2313) and double DBL5-6-e (residues 2026–2601)
domains were cloned into the pET28a expression vector between
the NdeI and BamHI restriction sites. FCR3 var2CSA sequences
were obtained by PCR over a synthetic gene template encoding
for var2CSA DBL5-6-e, designed with optimized codons for E. coli
expression, and using the following oligonucleotides:
FCR3-DBL5-6-For, 59-GAAGGAGATATACATATGCTGA-
TTGCGGATGG-39; FCR3-DBL6-For, 59-GACACGGAGAT-
CATATGGCGTTCAAACAAATCAAAGAACAGG-39; FCR3-
DBL5-Rev, 59-TCCGTCAGGATCCTTAAAAGCCGCACGG-
GC-39; FCR3-DBL6-Rev, 59-TCCGTCAGGATCCTATTCT-
TTCAGATAATCCGGCGC-39. The other strains sequences
were obtained by PCR over the corresponding genomic DNA
template using the following oligonucleotides: 7G8-Dd2-DBL5-
For, 59-GAAGGAGATATACATATGTTAATTGGAGATGC-
39; HB3-DBL5-For, 59-GAAGGAGATATACATATGTTAAT-
TGCAGATGCTATAGG-39; 7G8-HB3-DBL5-Rev, 59-TCCG-
TCAGGATCCTTAAAATCCACACGGAC-39; Dd2-DBL5-Rev,
59-TCCGTCAGGATCCTAAAAACGACATGAAC-39; HB3-D-
BL5-6-Rev, 59-TCCGTCAGGATCCTTATCTTTCAAGTAC-
TCATG-39.
1.2. Expression. Transformed E. coli BL21 (DE3) cells were
grown at 37uC in LB medium with 30 m g/ml of kanamycin to an
absorbance of 0.5 at 600 nm, and were then induced with 1.0 mM
isopropyl-b-D-thiogalactopyranoside (IPTG) for 3 h at 37uC
under good aeration. For DBL6-e soluble expression induction
was performed with 0.1 mM IPTG, overnight at 20uC. Cells were
harvested by centrifugation at 6000 g. The pellets of culture were
resuspended in 50 mM Tris.HCl, pH 8.5, containing 150 mM
NaCl. The cells were disrupted by sonication on ice and the
suspensions were centrifuged for 20 min at 5000 g.
1.3. Refolding and Purification. FCR3-DBL6-e was
expressed as a soluble protein in the soluble fraction and
therefore purified from the supernatant using a HisTrap FF Ni-
affinity column. After this single purification step, protein yield
(not optimized conditions) was 2.5 mg/liter of culture. For all the
other proteins, expressed as insoluble inclusion bodies, pellets
were resuspended and washed twice with 30 ml of 50 mM
Tris.HCl, pH 8.5, containing 150 mM NaCl and finally
centrifuged for 20 min at 10000 g. The pellets containing
inclusion bodies were then denatured during 2 h at 25uCu n d e r
agitation in 50 mM Tris.HCl pH 8.0, containing 200 mM NaCl,
2.0 mM EDTA, 7.0 M GuHCl and 10 mM TCEP. The
suspensions were centrifuged for 30 min at 15000 g and the
pellet was discarded.
Refolding was assayed with the IFOLD
TM Protein Refolding
System 2 (Novagen) according to the manufacturer’s instructions.
Once the best condition was established, each denatured protein
was refolded by rapid dilution (1:50, 5 mg/mL) and maintained
with gently shaking overnight. Composition of the refolding
solutions were as follow: 50 mM TAPS pH 8.5, 0.5 M NDSB-
256, 6.0 mM reduced glutathione, 4.0 mM oxidized glutathione,
240 mM NaCl, and 10 mM KCl (for DBL5-e domains); 50 mM
Hepes pH 7.5, 6.0 mM reduced glutathione, 4.0 mM oxidized
glutathione, 240 mM NaCl, and 10 mM KCl (for DBL5-6-e
domains). After refolding, solutions were centrifuged for 30 min at
20000 g to eliminate aggregated proteins. Supernatants were
passed on a HisTrap FF Ni-affinity column previously equilibrated
with the same buffer, and connected to an FPLC Akta System.
Proteins were eluted with an imidazole gradient (0 to 0.5 M) and
aliquots containing each purified DBL domain were pooled. After
dialysis against PBS and concentration by means of Macro- and
Micro-sep concentrators, a further stage of gel filtration (Superdex
75, Amersham Pharmacia Biotech) was required to separate the
aggregated material from the monomeric proteins and other
impurities. Purified DBLs were subsequently concentrated by
means of Macro- and Micro-sep concentrators. Protein concen-
tration was determined using the Bio-Rad protein assay. Purity of
the samples was checked by SDS-PAGE and Western blot, under
reduced (by adding DTT) or non reduced conditions.
Protein yields (not optimized conditions) after refolding and all
purification steps were 3.0 mg/liter of culture for FCR3-DBL5-e,
0.4 mg/liter of culture for 7G8-DBL5-e, 0.5 mg/liter of culture
for HB3-DBL5-e, 1.0 mg/liter of culture for Dd2-DBL5-e,
1.5 mg/liter of culture for FCR3-DBL5-6-e, and 0.5 mg/liter of
culture for HB3-DBL5-6-e.
2. Immunizations
Groups of five Balb/c mice (Charles River) received a primary
subcutaneous injection of 20 mg recombinant antigens dissolved
in 100 ml of NaCl 0.9% and emulsified at 1:1 in 100 mlo f
complete Freund’s adjuvant or 100 ml of Alum (Thermo
Scientific- Rockford IL USA). Two additional injections were
performed at days 14 and 42 after the first injection using the
same amount and antigen batches emulsified at 1:1 in incomplete
Freund’s adjuvant or in Alum. Mice were bled by orbital sinus
puncture one day before the primary antigen injection and each
time preceding an antigen boost. Ex-sanguination was performed
at day 70 after primary injection. Serum samples were collected
after centrifugation of the blood, and decomplemented for
30 min at 56uC. Goat was immunized using primary intramus-
cular injection of 200 mg refolded recombinant antigen dissolved
in 1 ml of NaCl 0.9% and emulsified at 1:1 in 1 ml of Alum. Two
additional injections were performed at days 35 and 70 after the
first injection using same amount and antigen batches emulsified
at 1:1 in 1 ml of Alum.
Adhesion Blocking Antibodies
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e125583. IgG Purification and depletion
Hitrap protein G (GE, USA) was used according to manufac-
turer’s instructions for IgG purification of mouse or goat plasma.
Bound IgG was eluted in 0.5 ml fractions using 100 mM Glycin
pH 2.5 (tubes were preloaded with 50 ml 1 M Tris.HCl pH 8.0 for
neutralization) and diafiltrated against PBS pH 7.2. Dynabeads
coated with FCR3 recombinant DBL5-6-e was used to deplete
goat IgG from anti DBL5-6-e antibodies. 100 mg of recombinant
FCR3-DBL5-6-e were coated on 166 ml washed Dynabeads M-
280 tosylactivated (Invitrogen Dynal, Oslo, Norway) prepared
according to manufacturer’s indications. Aliquots of 166 mlo f
beads were washed three times in 900 ml PBS pH 7.4 using the
magnetic particle concentrator (Dynal) and resuspended in the
same buffer. The washed beads were mixed with 100 mg (1 mg/
ml) of protein, 1.2 M ammonium sulfate and incubated 24 h at
37uC with slow tilting. After incubation beads were washed five
times with 1 ml PBS, incubated 1 h at 37uC with PBS, 0.5% BSA
and washed 2 times in PBS. The beads were stored in same buffer.
100 ml of purified IgG at 5 mg/ml were incubated during one
hour with the coated beads. The flow through was used for flow
based inhibition assay. The coated magnetic beads were washed
four times with 1 ml PBS and the antibodies were eluted with
0,1 M glycine pH 2.5. Eluted fractions were neutralized with
Tris.HCl 1 M pH 8.0. Pre-immune goat IgG was depleted in the
same condition and used as control.
4. Cell Culture
The FCR3 strain was grown in RPMI 1640 supplemented with
bicarbonate, glutamine, 0.2% glucose, 50 mM hypoxanthine, 10
mg/ml gentamicin, 25 mM HEPES and 0.25% Albumax
Figure 1. Expression and purification of recombinant var2CSA domains. (A) Purification after refolding of FCR3 var2CSA DBL domains
expressed in E. coli. Electrophoresis of purified DBL domains under reduced (+DTT) or non-reduced conditions on NuPAGE Novex 4–12% Bis-Tris gels,
Coomasie bleu stained. Arrows indicate the expected proteins. (B) FCR3-DBL5-6-e recombinant domain competes the adhesion of var2CSA
expressing FCR3-PEs but fails to inhibit binding of FCR3
CD36 parasites on CD36 receptor. The adhesion of FCR3-PEs was tested in flow binding assays
using ScC2 cells. FCR3-DBL5-6-e recombinant protein inhibited FCR3
CSA parasite binding in a phenotype specific and dose-dependent manner.
doi:10.1371/journal.pone.0012558.g001
Adhesion Blocking Antibodies
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Saimiri brain microvascular endothelial [20] and the human
choriocarcinoma-derived cell line BeWo (ATCC Nr CCL98) were
grown in DMEM/F12 (Sigma) supplemented with bicarbonate,
glutamine, 10 mg/ml gentamicin, 10% fœtal calf serum (Gibco)
and 15 mg/l endothelial cell growth supplement (Sigma). The cells
were grown in a humidified atmosphere in 5% CO2.
5. Flow-based Cytoadhesion Assay
ScC2 or BeWo cell suspensions were grown on Slideflask (Nunc
DK) to confluence. The slides were then mounted in a cell
adhesion flow chamber CAF 10 (Immunetics, Boston MA, USA)
and held in place by vacuum. The system was connected to a
precise perfusion peristaltic pump P720 (Instech laboratories Inc,
Winsum, NL). The outlet of the perfusion chamber was connected
to reservoirs containing PE suspension in cytoadhesion medium
(RPMI, pH=6,8) [21]. Cytoadhesion was observed with an
inverted microscope (Nikon Eclipse TE200, Japan) using Plan Apo
10/0,45 objective (Nikon) coupling to camera and Lucia 4.8
software (Nikon) for the numeration. For the recombinant protein
inhibition assays, slides were preincubated with the indicated
quantities diluted in cytoadhesion medium for 1 h at 37uC. An
aliquot of 1 ml of PE suspension at 2610
7/ml incubated 15 min at
37uC with purified antibodies, CSA (Sigma), or only medium, was
allowed to flow into the perfusion chamber over the ScC2 or
BeWo at 0.05 Pa. We then allowed cytoadhesion medium to flow
through the chamber for 10 min at 0.05 Pa to remove non-
adherent cells. The number of adherent PE/mm
2 was determined
in two to three independent experiments.
6. Flow Cytometry
Trophozoite-stage PEs were purified using gelatin flotation and
incubated with mice or goat sera that had been preabsorbed twice
with uninfected erythrocytes. For each assay, 10 million PEs were
incubated with a 1/10 dilution of sera. Bound antibodies were
detected by adding biotin-conjugated goat anti-mouse IgG (Sigma,
Saint Louis, MO) or biotin-conjugated rabbit anti-goat (ab7131,
Abcam) followed by fluorescein isothiocyanate (FITC)-conjugated
streptavidine (BD pharmingen, San Diego, CA). Analysis was
carried out by gating parasitized cells stained with 10 mg/ml of
Figure 2. Recombinant DBL5-e, DBL6-e, and DBL5-6-e domains induce antibodies that block adhesion to BeWo cells in flow binding
assays. (A) Schematic representation of the binding inhibition assay mimicking the flow in placental physiological conditions (B) Inhibition of FCR3
PEs adhesion. Purified IgG at 0.5 mg/ml from a group of 5 mice immunized either with Freund or Alum as adjuvants were tested for inhibition of
binding of FCR3-PEs to BeWo cells in flow binding assays. The numbers of bound PEs in the presence of IgG from preimmune serum was used as a
reference value. The numbers of bound PEs for anti DBL IgG were used to calculate the binding inhibition as a percentage relative to the reference
value. (C) and (D) Recombinant domains from heterologous parasites induce transcending adhesion blocking activity. Purified IgG at 0.5 mg/ml from
groups of 5 mice immunized with heterologous DBL5-e and DBL5-6-e domains were tested for inhibition of binding of FCR3-PEs to BeWo and ScC2
cells in flow binding assays. Amino acid sequence identity percentages between the heterologous DBL domain and the homologous FCR3 DBL are
presented.
doi:10.1371/journal.pone.0012558.g002
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CellQuest software (BD Biosciences). At least 50000 cells were
counted for each sample, in two independent experiments.
Results
Expression and purification of recombinant DBL5-e,
DBL6-e and DBL5-6-e domains
Due to the large protein size, var2CSA-based vaccine
development is highly dependent on the production of functional
var2CSA protein subunits. Our previous analysis of mouse mAbs
directed against the surface of FCR3
CSA suggested that the C-
terminal region (DBL5-6-e) of var2CSA was frequently recognized
by adhesion blocking mAbs [22]. For this reason, we focused our
effort on DBL domains DBL5-e, DBL6-e, and double DBL5-6-e
domains. These domains were cloned into the pET28a vector
(Novagen, His-tag on the N-terminus) for subsequent expression
and purification. We expressed DBL5-e domains from FCR3,
Dd2, HB3, and 7G8 parasite strains, and DBL5-6-e domain from
FCR3 and HB3. Only FCR3-DBL6-e was expressed as a soluble
protein, whereas DBL5-e and DBL5-6-e accumulate in inclusion
bodies as insoluble aggregates.
FCR3-DBL6-e was purified by His-tag affinity from the
supernatant obtained after lysis of bacteria and centrifugation
(Figure 1A). Highly pure (over 95%) recombinant protein was
obtained at a yield of 2.5 mg/liter of culture. No further
purifications steps were necessary. Western blot analysis showed
that the larger band around 90 kDa corresponds to a dimer of
DBL6-e (data not shown).
Inclusion body containing DBL5-e and DBL5-6-e domains
were solubilized in a 7 M Guanidine.HCl buffer and refolding
tests were carried out by the method of rapid dilution. Using this
strategy, the best solutions for refolding of each insoluble domain
were chosen according to relative criteria of yield, solubility and
his-tag affinity. After affinity purification all proteins solutions
were dialysed against PBS. Several bands were observed for
FCR3-DBL5-6-e on a SDS-PAGE (Figure 1A). N-terminal
sequencing and western blot using anti-His-tag suggest that these
proteins are degradation products derived from FCR3-DBL5-6-e.
In our hands shift in gel migration of cysteine-rich proteins in the
presence of DTT as reducing agent were not systematically
observed. A slight shift in migration for FCR3-DBL5-e can be
observed in Figure 1A. The absence of shift for FCR3-DBL6-e
was already observed for this domain when expressed in an
eukaryotic system (HEK293 Cells) where these disulfide bridges
are normally produced [16].
In a previous study, we showed that DBL6-e expressed on the
surface of CHO cells binds to CSA-coated beads [11]. The
recombinant var2CSA FCR3-DBL5-6-e purified protein was
capable to compete in a dose-dependent manner the binding of
FCR3
CSA PEs to ScC2 cells while not affecting the FCR3
CD36 PEs
(Figure 1B). This result indicates that the refolded recombinant
protein is in a functional conformation. HB3-DBL5-6-e showed
similar results when expressed, refolded and purified using the
same conditions as for FCR3-DBL5-6-e (data not shown).
Anti DBL5-e, DBL6-e, and DBL5-6-e antibodies inhibit
adhesion to BeWo cells under flow conditions
To investigate whether the recombinant var2CSA domains could
induce biologically active antibodies, groups of five mice were
immunized with FCR3-DBL6-e and FCR3-DBL5-6-e recombinant
proteins. Two different adjuvants were compared in this test:
Freund and Alum. Final bleed antisera were pooled for each group,
IgG purified and evaluated for their capacity to recognize the
surface of FCR3
CSA binding PEs by liquid immunofluorescence. All
IgG pools showed surface reactivity with CSA-panned but not with
CD36 panned parasites (data not shown).
The ability of the immune sera IgG to inhibit the binding of
FCR3
CSA PEs to the CSA expressing human placental derived
BeWo cell line [23] was assessed in a flow-based cytoadhesion
assay mimicking the physiological blood circulation in the human
placenta (Figure 2A). Mouse preimmune sera IgG were tested to
exclude non-specific inhibition. DBL6-e and DBL5-6-e antisera
IgG inhibited binding of FCR3
CSA PEs to BeWo cells with values
of 67.4% and 73.8% for Freund’s group and 89.9% and 96.6% for
Alum’s group, respectively (Figure 2B). FCR3-DBL5-e antisera
IgG obtained with Freund as adjuvant inhibited binding of
FCR3
CSA PEs to BeWo cells at 35.5% (Figure 2C).
Figure 3. Recombinant FCR3-DBL5-6-e depletes the adhesion blocking activity in goat serum. (A) Goat Immunization with FCR3-DBL5-6-
e induces adhesion blocking antibodies. Goat purified IgG was tested for inhibition of FCR3-binding of PEs to BeWo and ScC2 cells in flow binding
assays after the first boost, second boost and four weeks after the second boost. (B) Recombinant FCR3-DBL5-6-e depletes the adhesion blocking
activity. Goat purified IgG obtained four weeks after the second boost (D98) was depleted on immobilized FCR3-DBL5-6-e. The inhibition of FCR3-PEs
adhesion of IgG before antigen depletion, the depleted IgG, and elution of anti DBL5-6-e were tested in flow binding assays using BeWo and ScC2
cells.
doi:10.1371/journal.pone.0012558.g003
Adhesion Blocking Antibodies
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crossreact with FCR3
CSA binding strain
Given the promising results obtained with Alum, all new
immunizations were done with this adjuvant. Groups of five mice
were immunized with Dd2-DBL5-e,H B 3 - D B L 5 - e, 7G8-DBL5-e,
and HB3-DBL5-6-e recombinant antigens. The ability of the
antisera IgG to inhibit the binding of FCR3
CSA PEs to the CSA
expressing human placental derived BeWo cell line [23] and the
Figure 4. Recognition of antigens expressed on the surface of PEs. Mouse and goat sera raised against DBL domains were assayed for their
binding capacity to the surface of erythrocytoes infected with parasites of the FCR3 strain with CSA- and CD36-binding phenotypes. Analysis was
performed using flow cytometry. Panels represent number of events (counts) against fluorescence (FITC) for each antiserum (doted line) when
compared to the pre-immune serum (full line). FCR3
CSA parasite binding inhibition on BeWo cells are indicated for the respective antisera.
doi:10.1371/journal.pone.0012558.g004
Adhesion Blocking Antibodies
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system. All IgG pools inhibited binding of FCR3
CSA PEs when
compared to the preimmune sera IgG with values ranging from
32.7%to 77.6% (Figure 2C and2D).Itis noteworthy,thatinhibition
on BeWo cells gave slightly higher inhibition levels when compared
to monkey brain endothelial cell line ScC2 expressing CSA.
DBL5-6-e elicits cytoadhesion blocking antibodies in goat
that can be depleted with recombinant DBL5-6-e protein
While mice offer the advantage of working in a consistent
genetic background, are easy to handle, and are very cost-effective,
they provide limited quantities of serum for IgG characterization
under flow adhesion. We therefore immunized a goat with
var2CSA FCR3-DBL5-6-e recombinant domain and tested the
produced antisera over time for their ability to recognize the native
var2CSA in FCR3
CSA PEs by liquid immunofluorescence and
their capacity to inhibit the binding of FCR3
CSA PEs to BeWo and
ScC2 cells. One goat was immunized with 200 mg of var2CSA
FCR3-DBL5-6-e recombinant domain using Alum as adjuvant,
followed by boosts of equal amounts of antigen at day 35 and day
70. Samples were taken five weeks after the first boost (D70) and
two (D84), and four (D98) weeks after the second boost. The IgG
purified from sera was able to recognize specifically FCR3
CSA PEs
by liquid immunofluorescence (data not shown), and inhibited the
binding to BeWo (approx. 50%) and ScC2 cells (64 to 18%)
(Figure 3A). To investigate if this binding inhibition was specific to
anti DBL5-6-e antibodies, we immobilized the FCR3-DBL5-6-e
recombinant antigen in tosylactivated beads and adsorbed a
fraction of D98 goat antisera IgG. When measuring binding under
flow conditions the IgG sample flow through lost its binding
inhibition capacity. Elution of retained IgG allowed the recovery
of inhibition ability to similar levels as before treatment (Figure 3B).
Antibodies against homologous and heterologous
DBL5-e and DBL5-6-e domains react differentially with
the surface of FCR3 PEs
In order to investigate if surface reactivity with FCR3 PEs could
be predictive for inhibition of adhesion to the placenta, we
measured the reactivity of our mouse and goat antisera with live
PEs using flow cytometry. The results are shown in figure 4. All
sera directed against the FCR3-DBL5-6-e domains reacted
strongly with the homologous FCR3 parasite at serum dilutions
1/10. The anti FCR3-DBL5-e antibodies had been used up for
inhibition studies. The antibodies raised against DBL5-e and
DBL5-6-e from heterologous parasites (HB3, 7G8 and Dd2)
showed a weak surface reactivity with FCR3, suggesting that a
large portion of the surface antibodies is allele specific.
Nonetheless, the binding inhibition of these heterologous antibod-
ies was generally .60% using FCR3
CSA parasites. This result
obtained with anti recombinant DBL antisera has important
implications since it shows that surface reactivity is not predictive
for binding inhibition.
Discussion
In this work we showed that recombinant DBL domains
corresponding to the C-terminal var2CSA external region
generate strong cytoadhesion-blocking antibodies (.50% inhibi-
tion at 0.5 mg/ml) in different experimental animals. Further-
more, we also show that the inhibitory antibodies are specifically
targeting the antigen as the inhibition capacity is lost after
depletion of the antisera with the recombinant protein.
The use of VAR2CSA as a vaccine candidate to prevent PAM is
hampered by its high molecular weight together with its
hydrophobic and cysteine-rich sequence as major restrictions for
production of sufficient functional full-length recombinant protein.
Although recent reports show that the expression of the entire
external domain of var2CSA is now possible [12,13], its use for
vaccine development is obviously limited due to the constraints in
up-scaling production. Several epitopes have been described in
var2CSA, which induce cytoadhesion-blocking antibodies [16–
18]. A major research effort is currently dedicated to explore the
degree of cross-reactivity with other alleles.
DBL5 is one of the most conserved var2CSA regions, its allelic
forms vary between 66% for Dd2 to 81% for HB3 when compared
to the reference strain FCR3. Immunization with three heterol-
ogous DBL5 allelic forms generated cytoadhesion-blocking
antibodies to the reference strain FCR3. Importantly, this
transcending biological activity has been obtained in an assay
system that mimics closely placental flow of parasites. Our results
are not totally in line with already published data using different
expression systems. For example DBL5-e expressed in Pichia
pastoris induces highly cross-reactive antibodies but with limited or
no inhibitory activity [25]. In addition only very limited parasite
inhibition using DBL5-specific serum was obtained in another
laboratory (DBL5-e produced in the baculovirus expression
system) [18]. The observed variation in adhesion blocking
antibodies between laboratories may be the result of DBLs
generated in different protein expression systems, which may
produce slightly different DBL conformations. It is also possible
that antibody mediated desequestration is more easy on BeWo
cells than on plastic coated CSA. This is the first study which
analyzes sera from PAM vaccine candidates in a flow assay using
placental trophoblastic cell line. Our data are very promising and
point to DBL5 as a subunit vaccine with a high desequestration
potential. The next important step will be to evaluate the efficacy
of inhibition of placental isolates from distinct geographic regions.
In conclusion, our results clearly show that a single DBL
domain produced in E. coli can achieve significant levels of parasite
cytoadhesion inhibition on placental cells. Given the transcending
immune response against the relatively conserved DBL5 domain
this antigen is likely to inhibit sequestration of infected red blood
cells in the placenta. The fact that the immunogenicity is
potentiated by the use of Alum, an adjuvant used in humans is
very promising for next steps. At this stage, we cannot exclude that
the development of an efficacious subunit-based recombinant
vaccine against PAM might require a cocktail of subunit antigens.
Further studies on clinical isolates are necessary to validate our
findings.
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